ReviewRheumatology international2026
Bilateral temporal arteritis with multiorgan eosinophilic infiltration treated with IL-5 targeted antibody.
Review in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporal arteritis with marked eosinophilic infiltration is uncommon and can present as either a localized arteritis or a manifestation of systemic eosinophilic disease. We report a 48-year-old woman who presented with fatigue, intermittent fever, and bilateral painful cord-like swelling in the frontal region. Laboratory tests showed marked eosinophilia and elevated total IgE with mild inflammation, while anti-neutrophil cytoplasmic antibodies were negative. Biopsies of both superficial temporal arteries demonstrated transmural eosinophilic infiltration with disruption of the internal elastic lamina and intraluminal thrombosis without giant cells or granulomas. During follow-up, the patient developed hepatobiliary enzyme elevation, and biopsies of the esophagus, liver, and a breast mass confirmed eosinophilic infiltration. Bone marrow examination showed eosinophilic hyperplasia without evidence of a myeloproliferative neoplasm and no FIP1L1-PDGFRA fusion was detected. These findings supported a diagnosis of hypereosinophilic syndrome (HES) with temporal artery involvement. Prednisolone improved systemic symptoms, but temporal arteritis relapsed during tapering and was refractory to methotrexate. The addition of mepolizumab achieved sustained remission and enabled further glucocorticoid (GC) reduction. This case highlights that bilateral or GC-dependent eosinophilic temporal arteritis warrants evaluation for systemic eosinophilic disorders, and suggests that IL-5 blockade can be an effective GC-sparing strategy in HES.
Indexed as
Identifiers
42207305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.